The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
- Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
- Ethical Drug Sales Down 1.4% in February: Crecon Report
April 10, 2015
- IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate
April 10, 2015
- Livalo Shows No Negative Effects on Fasting Blood Glucose Levels, HbA1c: Kowa
April 10, 2015
- Regience Partners with Keio Univ. for Joint Research of Liver Regeneration
April 10, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
April 9, 2015
- Novo Nordisk’s Japan Sales Bounce Back to Hit All-Time High
April 9, 2015
- Hisamitsu Sales Up 4.1% despite Dull Japan Biz, Mohrus Down 8.5%
April 9, 2015
- Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
- Bayer Yakuhin Negotiating with Universities, Institutions for Research Agreements
April 9, 2015
- Merck KGaA, Pfizer to Copromote Xalkori in Japan, US, Europe
April 9, 2015
- Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
- BIKEN, Osaka University Strike License Agreement to Develop Novel Pneumococcal Vaccines
April 8, 2015
- Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
- Mochida Using “Granular Tablets” to Gain Share in Generic Drug Market
April 7, 2015
- Pfizer Japan Rolls Out Japan’s 1st Propecia Generic
April 7, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…